Truseltiq, also known as infigratinib, is a medication that has shown promising results in the treatment of certain types of cancer. Specifically, Truseltiq is approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.

As a medical professional, it is important to understand the mechanism of action of Truseltiq. This medication works by inhibiting FGFR, a protein that plays a key role in the growth and spread of cancer cells. By targeting this specific pathway, Truseltiq has been shown to effectively slow down the progression of cholangiocarcinoma in patients who have not responded to other treatments.

It is crucial to discuss the potential side effects of Truseltiq with patients before starting treatment. Common side effects may include hyperphosphatemia, stomatitis, dry mouth, fatigue, and changes in liver function tests. It is important for patients to report any side effects to their healthcare provider promptly.

As with any medication, it is important for patients to follow their healthcare provider’s instructions carefully when taking Truseltiq. This may include taking the medication at the same time each day, avoiding certain foods or medications that may interact with Truseltiq, and attending regular follow-up appointments to monitor for any potential side effects.

Overall, Truseltiq represents a promising option for patients with certain types of cancer, and as a medical professional, it is important to stay informed about the latest developments in cancer treatment to provide the best care possible for our patients.